Lactobacillus Sakei CVL-001 Composition for NOD2-Mediated Inflammation Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for inflammatory diseases, such as ulcerative colitis and Crohn's disease, often cause side effects and there is a need for more effective and safer alternatives that can modulate the immune response.

Innovation Solution

A pharmaceutical or health functional food composition containing the Lactobacillus sakei CVL-001 strain, which activates NOD2, an inflammation regulatory factor, to inhibit body weight loss and improve disease activity indices in animal models.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If immunosuppressants are used to treat inflammatory diseases, then the treatment effectiveness is improved, but side effects such as nausea, heartburn, headache, dizziness, anemia, and skin rashes occur

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses Lactobacillus sakei CVL-001 strain as an intermediary substance to modulate the immune system's response to inflammatory diseases. Instead of directly suppressing the immune system with immunosuppressants, this probiotic strain acts as a mediator that regulates immune function through its metabolic activities and interaction with gut microbiota, thereby reducing inflammation while avoiding the harsh side effects of conventional immunosuppressive drugs

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs a biologically active strain that can be administered as a living organism rather than relying on long-term pharmacological intervention. The Lactobacillus sakei CVL-001 strain serves as a temporary, self-limiting therapeutic agent that performs its immunomodulatory function and then naturally expires, avoiding the cumulative toxicity and long-term side effects associated with continuous immunosuppressant use

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

2Ease of operation

If conventional treatments are used for inflammatory diseases, then symptom control is achieved, but the quality of life is reduced due to side effects and repeated remission-recurrence cycles

Engineering Contradiction:

Improvesymptom controlVSAvoidquality of life reduction

Core Design Contradiction:

Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The patent enables the patient's own gut microbiota and immune system to serve the therapeutic function. The Lactobacillus sakei CVL-001 strain colonizes the gut and works synergistically with the host's immune system to regulate inflammation, turning the body's own biological systems into the treatment mechanism rather than relying on external pharmacological agents that cause side effects

Inventive Principle:

Principle #25Self-service

Data Source

PatentUS12496319B2Inflammatory diseases, comprising <i>Lactobacillus sakei </i>CVL-001 strain

Publication Date: 2025.12.16 IND FOUND OF CHONNAM NAT UNIV

AI summary

The present invention relates to a composition for preventing or treating inflammatory diseases, comprising a Lactobacillus sakei CVL-001 strain. The composition activates NOD2, which is an inflammation regulator, and exhibits the effects of inhibiting weight loss and improving clinical activity scores (disease activity index; DAI) in an animal model in which ulcerative colitis is induced, and thus the present invention can be effectively used in the prevention, treatment or alleviation of inflammatory diseases.